tiprankstipranks
Trending News
More News >

Argenica Therapeutics Bolsters Board for Growth

Argenica Therapeutics Bolsters Board for Growth

Argenica Therapeutics Ltd (AU:AGN) has released an update.

Confident Investing Starts Here:

Argenica Therapeutics has enhanced its board with the addition of Dr. Mark Etherton and Mr. Rob Black, bringing in a wealth of expertise in neurology drug development and financial markets. The appointments are set to bolster Argenica’s transition into a pharmaceutical development company, focusing on novel therapeutics for brain injuries and neurodegenerative diseases. The company is actively pursuing clinical trials for its lead neuroprotective peptide candidate, ARG-007, aimed at improving outcomes for stroke and other brain injury patients.

For further insights into AU:AGN stock, check out TipRanks’ Stock Analysis page.

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.

Report an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1